A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Parallel-Design Study to Evaluate the Short-Term, Fixed Dose Efficacy and Safety of LY110140 Once Daily Dosing in Japanese Patients With Major Depressive Disorder
Phase of Trial: Phase III
Latest Information Update: 08 Nov 2018
At a glance
- Drugs Fluoxetine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 23 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 May 2014 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
- 11 Dec 2013 Planned End Date changed from 1 Sep 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.